ReviewCurrent hypertension reports2016
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.
Review in Current hypertension reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.European journal of drug metabolism and pharmacokinetics · 2021Trial
- Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.Advances in therapy · 2019Trial
- Pannexins in the vasculature.American journal of physiology. Heart and circulatory physiology · 2025Review
- Latest hypertension research to inform clinical practice in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Timing of procedural interventions in childhood renovascular hypertension.Pediatric nephrology (Berlin, Germany) · 2021Article
- Antisense Inhibition of Angiotensinogen With IONIS-AGT-LJACC. Basic to translational science · 2021Article
- DNA Methylation of the Angiotensinogen Gene,International journal of molecular sciences · 2021Review
- Article
- Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Review
- Aliskiren Reduces the Adrenal Zona Glomerulosa Apoptosis and Autophagy in Wistar Rats with 2K1C Hypertension.International journal of hypertension · 2020Article
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Review
- Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.Circulation research · 2018Article
- Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.American journal of nephrology · 2018Article
- Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.American journal of physiology. Heart and circulatory physiology · 2017Article
- Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?Current hypertension reports · 2017Review
- Novel approaches for treating hypertension.F1000Research · 2017Review
- Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.Vascular health and risk management · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Treatment resistant hypertension (TRH), defined as a blood pressure above goal despite treatment with optimally tolerated doses of 3 antihypertensive agents of different classes, ideally including a diuretic, remains a significant problem and its management an area of uncertainty for physicians. One hypothesis is that resistant hypertension is due to abnormal sodium retention, mediated by aldosterone breakthrough occurring despite blockade of the renin-angiotensin-aldosterone system with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). Thus, there has been renewed interest in the use of mineralocorticoid receptor blockers (MRB) to treat this condition. This article critically evaluates new evidence supporting the use of MRB in TRH published in the last 3 years. We conclude that there is now sufficient evidence to recommend MRB, in particular spironolactone, as the first choice medication to treat this condition, and for its inclusion in future guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.